Company news

Seastar Medical Holding Corporation (NASDAQ:ICU) news

Seastar Medical Holding Corporation news releases on 6ix. Latest, Oct 5, 2026: SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million…

Seastar Medical Holding Corporation (NASDAQ:ICU) news

Press releases & updates

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury

SeaStar Medical to Present at Upcoming Investor Summit Conference

SeaStar Medical Reports First Quarter Financial Results and Provides Business Updates

SeaStar Medical to Report First Quarter Financial Results on May 13, 2026

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

ICU: Publication Validates Real-World Clinical Impact of QUELIMMUNE™ in Pediatric AKI

SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

SeaStar Medical Announces 2026 Milestones

SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference

SeaStar Medical Announces 1-for-10 Reverse Split

SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

SeaStar Medical Announces Appointment of Michael Messinger as CFO

SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Announces Positive Nasdaq Listing Determination

SeaStar Medical Reports Update on Nasdaq Listing Status

SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy

SeaStar Medical Announces Pricing of Up to $8 Million Public Offering

AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates